

[54] NON-IMMUNOGENIC POLYPEPTIDES

[76] Inventors: Frank F. Davis, 19 Farmingdale Rd.,
East Brunswick, N.J. 08816;
Theodorus Van Es, 313 Overbrook
Rd., Piscataway, N.J. 08854;
Nicholas C. Palczuk, 45 W. Franklin
St., Bound Brook, N.J. 08805

[21] Appl. No.: 819,831

[22] Filed: Jul. 28, 1977

[56]

References Cited

U.S. PATENT DOCUMENTS

3,607,653	9/1971	Ziffer et al.	195/63
3,619,371	11/1971	Crook et al.	195/63
3,639,213	2/1972	Ginger et al.	195/63
3,645,852	2/1972	Axon et al.	195/68
3,788,948	1/1974	Kagedal et al.	195/68
3,959,080	5/1976	Orth et al.	195/68 X
4,002,531	1/1977	Royer	195/DIG. 11
4,055,635	10/1977	Green et al.	195/DIG. 11

Primary Examiner—David M. Naff
Attorney, Agent, or Firm—Omri M. Behr

[57]

ABSTRACT

Polypeptides such as enzymes and insulin are coupled to polyethylene glycol or polypropylene glycol having a molecular weight of 500 to 20,000 daltons to provide a physiologically active non-immunogenic water soluble polypeptide composition. The polyethylene glycol or polypropylene glycol protect the polypeptide from loss of activity and the composition can be injected into the mammalian circulatory system with substantially no immunogenic response.

27 Claims, No Drawings

Related U.S. Application Data

- [63] Continuation-in-part of Ser. No. 596,931, Jul. 17, 1975,
abandoned, which is a continuation-in-part of Ser. No.
381,191, Jul. 20, 1973, abandoned.
- [51] Int. Cl.² C07G 7/00; C07G 7/02;
A61K 37/26; A61K 37/48
- [52] U.S. Cl. 435/181; 260/112.5 R;
260/112.7; 424/78; 424/94; 424/177; 424/178;
435/180
- [58] Field of Search 195/63, 68, DIG. 11;
424/94, 177, 178, 78; 260/112.5, 112 R, 6, 8,
112.7